Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL679593 | 1.00 | SLC7A5 (0.33) | SLC7A5 | |
| SCHEMBL5283576 | 1.00 | SLC7A5 (0.33) | SLC7A5 | |
| SCHEMBL719518 | 0.98 | SLC7A5 (0.32) | SLC7A5 | |
| SCHEMBL4939776 | 0.98 | SLC7A5 (0.32) | SLC7A5 | |
| SCHEMBL667476 | 0.83 | — | — | |
| SCHEMBL17627358 | 0.83 | — | — | |
| SCHEMBL6156936 | 0.82 | — | — | |
| SCHEMBL27768915 | 0.82 | AKR1B1 (0.30) | — | |
| SCHEMBL28059879 | 0.82 | AKR1B1 (0.30) | — | |
| SCHEMBL7052027 | 0.81 | SLC7A5 (0.38) | SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 419 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10881629-B2 | Methods and compositions for increasing the anaerobic working capacity in tissues | NATURAL ALTERNATIVES INTERNATIONAL, INC. (US) | 2021-01-05 | — | — | US | claimed |
| US-20190038583-A1 | METHODS AND COMPOSITIONS FOR INCREASING THE ANAEROBIC WORKING CAPACITY IN TISSUES | NATURAL ALTERNATIVES INTERNATIONAL, INC. | 2019-02-07 | — | — | US | claimed |
| US-20180353607-A1 | LIPIDS FOR DELIVERY OF THERAPEUTICS | MARINA BIOTECH INC (US) | 2018-12-13 | — | — | US | claimed |
| US-20180263982-A1 | CARBONIC ANHYDRASE ENZYMES FOR REGULATING MAST CELL HEMATOPOIESIS AND TYPE 2 INFLAMMATION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2018-09-20 | — | — | US | claimed |
| US-9907770-B2 | Methods and compositions for increasing the anaerobic working capacity in tissues | NATURAL ALTERNATIVES INTERNATIONAL, INC. (US) | 2018-03-06 | — | — | US | claimed |
| US-9821067-B2 | Lipopeptides for delivery of nucleic acids | MARINA BIOTECH, INC. (US) | 2017-11-21 | — | — | US | claimed |
| US-20170202796-A1 | METHODS AND COMPOSITIONS FOR INCREASING THE ANAEROBIC WORKING CAPACITY IN TISSUES | LEGACY CORPORATE LENDING, LLC, AS ADMINISTRATIVE AGENT | 2017-07-20 | — | — | US | claimed |
| US-9668994-B2 | Methods and compositions for increasing the anaerobic working capacity in tissues | NATURAL ALTERNATIVES INTERNATIONAL, INC. (US) | 2017-06-06 | — | — | US | claimed |
| CN-101309688-B | Compositions and methods for sustained release of beta-alanine | 自然选择国际公司 | 2016-06-22 | — | — | CN | claimed |
| US-20160058870-A1 | LIPOPEPTIDES FOR DELIVERY OF NUCLEIC ACIDS | MARINA BIOTECH INC (US) | 2016-03-03 | — | — | US | claimed |
| EP-0918469-B1 | METHODS AND COMPOSITIONS FOR INCREASING THE ANAEROBIC WORKING CAPACITY IN TISSUES | HARRIS ROGER C (GB) | 2001-11-07 | — | — | EP | claimed |
| WO-2001060961-A1 | STABLE, AQUEOUS COMPOSITIONS FOR TREATING SURFACES, ESPECIALLY FABRICS | THE PROCTER & GAMBLE COMPANY (US) | 2001-08-23 | — | — | WO | claimed |
| US-20010005579-A1 | Providing an amount of beta-alanine and L-histidine to blood or blood plasma effective to increase beta-alanylhistidine dipeptide synthesis in a tissue, exposing tissue to blood or plasma to increase accumulation of dipeptide in the tissue | NATURAL ALTERNATIVES INTERNATIONAL, INC. | 2001-06-28 | — | — | US | claimed |
| US-6172098-B1 | ADDING ALANINE AND HISTIDINE TO BLOOD TO INCREASE BETA-ALANYLHISTIDINE CONCENTRATION | NATURAL ALTERNATIVES INTERNATIONAL, INC. | 2001-01-09 | — | — | US | claimed |
| EP-1028706-A1 | BUFFERED DRUG FORMULATIONS FOR TRANSDERMAL ELECTROTRANSPORT DELIVERY | ALZA CORPORATION (US) | 2000-08-23 | — | — | EP | claimed |
| US-5965596-A | PROVIDING AN AMOUNT OF BETA-ALANINE TO BLOOD TO INCREASE BETA-ALANYLHISTIDINE DIPEPTIDE SYNTHESIS IN THE HUMAN TISSUE, SIMULTANEOUS ACCUMULATION OF CREATINE WITHIN A TISSUE | NATURAL ALTERNATIVES INTERNATIONAL, INC. | 1999-10-12 | — | — | US | claimed |
| EP-0918469-A1 | METHODS AND COMPOSITIONS FOR INCREASING THE ANAEROBIC WORKING CAPACITY IN TISSUES | HARRIS, Roger C. (GB) | 1999-06-02 | — | — | EP | claimed |
| WO-1999024015-A1 | BUFFERED DRUG FORMULATIONS FOR TRANSDERMAL ELECTROTRANSPORT DELIVERY | ALZA CORPORATION (US) | 1999-05-20 | — | — | WO | claimed |
| WO-1998006278-A1 | METHODS AND COMPOSITIONS FOR INCREASING THE ANAEROBIC WORKING CAPACITY IN TISSUES | HARRIS, ROGER (GB) | 1998-02-19 | — | — | WO | claimed |
| US-4427762-A | DEVELOPMENT WITH ALKALINE DEVELOPER MIXTURE | KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) | 1984-01-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180263982-A1 | CARBONIC ANHYDRASE ENZYMES FOR REGULATING MAST CELL HEMATOPOIESIS AND TYPE 2 INFLAMMATION | CA2, CMA1, CPA3 | SLC7A5 4311/4885 |
| US-20160058870-A1 | LIPOPEPTIDES FOR DELIVERY OF NUCLEIC ACIDS | LNPEP, LPXN, SLC27A1 | SLC7A5 125/4885 |
| US-20180353607-A1 | LIPIDS FOR DELIVERY OF THERAPEUTICS | APOB, ABHD16A, LIPA | SLC7A5 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.